Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release
about
Genes and chronic obstructive pulmonary diseaseImmune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceExpanding the clinical indications for α(1)-antitrypsin therapyAlpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatmentNasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune ResponsivenessRespiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidantsThe effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.Expression and Purification of Functionally Active Recombinant Human Alpha 1-Antitrypsin in Methylotrophic Yeast Pichia pastoris.Effect of recombinant α1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes.Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management.Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.The clinical potential of ex vivo lung perfusion.Ex vivo lung reconditioning: a new era for lung transplantation.Immune-modulating effects of alpha-1 antitrypsin.The multiple facets of alpha-1-antitrypsin.Alpha-1-antitrypsin inhibits nitric oxide production.Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model.Alpha(1)-antitrypsin inhibits epithelial Na+ transport in vitro and in vivo.Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes.Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages.Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment.The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions.Point Mutation of a Non-Elastase-Binding Site in Human α1-Antitrypsin Alters Its Anti-Inflammatory Properties.
P2860
Q24630805-107E1BF9-98E3-4D06-883B-E336A5B54C13Q26850621-9ECC94EC-B322-46D3-81BE-E36A59870E53Q27000764-4616793D-A655-4A37-9FC4-6FC99F0B2FEFQ33922982-C9F70061-0B9D-44F9-8D57-9368F8E1115EQ35031693-5FCE126C-D10C-4277-8D96-C4687CE367F2Q35179153-8781911B-1934-4313-9E75-E7B32F23490FQ35772526-555EB478-8C19-4418-938C-A50C0C8AAD76Q36104532-74FF6AE7-14E2-4F8A-9DB3-CA6DEC63FD89Q36308010-EC565F75-7848-4C70-B7C6-540B6984CBC6Q36571385-67A848A1-413D-4D81-9A01-8059F121C80AQ36885672-D6B3BB3D-826C-4206-8C16-25AE47F088E6Q37018904-B0360203-B4F2-4DEF-BFC2-AA66B104ED17Q37303247-D5B5D2B7-859C-41DF-B964-D8D8D75DBBA6Q37447482-B8610871-05C5-499D-AABA-014350500438Q37979247-E982D9F0-6760-4604-AF24-778559432672Q38071533-352377A5-4AEE-4DC5-B228-8B7D6CF06D3BQ38214040-36F79277-B0BE-4B7E-B046-65DAA4078C91Q38553419-142878BA-5911-458B-84B7-2D5A0BD78E06Q39279412-E6B4AA7B-36CC-47E8-8BBB-D24E7F9D0243Q39587262-9665A4D2-2CB9-4D55-B971-F7F8EE4E52AAQ39897500-FB09A7C6-45F9-4FFF-97D1-C6E1D0ECBD0DQ42590837-61130D32-396E-4191-9878-AC52DE0C228BQ51035349-15037DCA-04C5-42D5-8BAB-E679D96854DEQ51568269-E12D9AC0-BB32-4CB8-90DF-CBC51B48FDB2Q55259593-D9EFE63E-10D3-4AB3-9E9D-2E16BF838048Q55438350-38FBADE7-23B9-4482-B006-615624DEB159
P2860
Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@ast
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@en
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@nl
type
label
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@ast
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@en
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@nl
prefLabel
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@ast
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@en
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@nl
P2860
P356
P1433
P1476
Prolastin, a pharmaceutical pr ...... oxin-mediated cytokine release
@en
P2093
Camilla Hollander
Sabina-Marija Janciauskiene
P2860
P2888
P356
10.1186/1465-9921-6-12
P407
P577
2005-01-31T00:00:00Z
P5875
P6179
1012141287